HomeCompareSEEL vs ADC

SEEL vs ADC: Dividend Comparison 2026

SEEL yields 540.54% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SEEL wins by $112786.05M in total portfolio value
10 years
SEEL
SEEL
● Live price
540.54%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112786.22M
Annual income
$82,692,515,806.61
Full SEEL calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — SEEL vs ADC

📍 SEEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSEELADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SEEL + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SEEL pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SEEL
Annual income on $10K today (after 15% tax)
$45,945.95/yr
After 10yr DRIP, annual income (after tax)
$70,288,638,435.62/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, SEEL beats the other by $70,288,570,735.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SEEL + ADC for your $10,000?

SEEL: 50%ADC: 50%
100% ADC50/50100% SEEL
Portfolio after 10yr
$56393.20M
Annual income
$41,346,297,726.93/yr
Blended yield
73.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

SEEL
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-156.6
Piotroski
5/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SEEL buys
0
ADC buys
0
No recent congressional trades found for SEEL or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSEELADC
Forward yield540.54%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$112786.22M$176.9K
Annual income after 10y$82,692,515,806.61$79,647.25
Total dividends collected$110217.05M$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SEEL vs ADC ($10,000, DRIP)

YearSEEL PortfolioSEEL Income/yrADC PortfolioADC Income/yrGap
1← crossover$64,754$54,054.05$10,987$577.21+$53.8KSEEL
2$396,410$327,123.28$12,293$855.34+$384.1KSEEL
3$2,295,726$1,871,567.31$14,088$1,290.70+$2.28MSEEL
4$12,586,137$10,129,710.14$16,660$1,994.91+$12.57MSEEL
5$65,369,349$51,902,182.37$20,525$3,181.85+$65.35MSEEL
6$321,877,325$251,932,121.38$26,654$5,286.90+$321.85MSEEL
7$1,503,762,535$1,159,353,797.14$37,006$9,259.47+$1503.73MSEEL
8$6,671,013,644$5,061,987,731.83$55,862$17,338.74+$6670.96MSEEL
9$28,124,961,234$20,986,976,635.20$93,452$35,300.32+$28124.87MSEEL
10$112,786,224,327$82,692,515,806.61$176,931$79,647.25+$112786.05MSEEL

SEEL vs ADC: Complete Analysis 2026

SEELStock

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full SEEL Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this SEEL vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SEEL vs SCHDSEEL vs JEPISEEL vs OSEEL vs KOSEEL vs MAINSEEL vs NNNSEEL vs EPRTSEEL vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.